Blepharospasm Clinical Trial
Official title:
Clinical Trial of a Mechanical Device for the Treatment of Blepharospasm
Idiopathic blepharospasm (IB) is a rare but well characterised adult onset focal dystonia
that may cause severe visual disability. The most effective treatment is with periodic
injections of botulinum toxin into the pre-tarsal and / or pre-septal orbicularis oculi
muscles bilaterally. However, even with treatment, practical visual function often remains
compromised.
A subset of IB sufferers find that eye opening improves with focal unilateral digital
pressure usually on a specific point on the temple. The Investigators have developed a
spectacle mounted spring-loaded prosthesis (the "Pressop" device) to apply continuous
individually localised focal pressure on the temple to mimic the effect of finger pressure.
The Investigators recommended a trial of this simple safe device in those IB patients who
report improvement in eye opening with focal digital temple pressure.
Idiopathic blepharospasm is a rare chronic neuro-ophthalmic disorder that causes substantial
visual handicap & compromises quality of life. It affects adults, women more than men,
usually beginning in the 5th or 6th decade and consists of repeated forceful bilateral spasms
of eye closure with photophobia and ocular surface discomfort. In up to a third of cases
there are synchronous mid and / or lower facial spasms and the spectrum of disorder extends
to cranial dystonia involving jaw & neck muscle spasms (e.g. antecollis or retrocollis).
Practical visual function is variably affected but most patients will have to stop driving,
many cannot work, manage the house or even leave the house unaccompanied. Leisure activities
such as reading & watching television are compromised or impossible, and secondary mood
dysphoria and depression are common.
In some cases, patients have discovered that applying focal finger pressure, usually to the
temple, relieves or even abolishes the spasms for the duration of the application. It is,
however, difficult for the patient to sustain the finger pressure and impossible to apply it
during activities when eyesight is important e.g. driving, typing or other bimanual tasks.
The phenomenon can be regarded as the equivalent of the sensory trick (ST or geste
antagonistique) seen in some cases of spasmodic torticollis whereby finger tip pressure on
the chin prevents or reduces the muscle spasms in the neck and allows the head to be held
straight.
In this study, the Investigators explored the hypothesis that the benefit of the finger-tip
pressure sensory trick could be replicated by a spring-loaded, spectacle mounted device
applying focal pressure to the temple. Following preliminary design trials, the investigators
commissioned a manufacturer to develop a light easily handled pressure device that could be
fixed to the frame of most spectacles. The "Pressop" device fulfils these criteria and was
adopted for the trial.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01686061 -
Blepharospasm Patient Survey for Patients With Blepharospasm
|
||
Completed |
NCT00535938 -
MDs on Botox Utility (MOBILITY)
|
N/A | |
Recruiting |
NCT05027997 -
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
|
Phase 2 | |
Terminated |
NCT03263000 -
Photic Blink Reflex in People With Blepharospasm and Increased Blinking
|
||
Completed |
NCT03938363 -
Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia
|
N/A | |
Completed |
NCT02947815 -
Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
|
Phase 2/Phase 3 | |
Completed |
NCT00406367 -
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
|
Phase 3 | |
Completed |
NCT00682760 -
Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm
|
Phase 3 | |
Completed |
NCT00210431 -
Post Marketing Surveillance Study of Dysport
|
||
Completed |
NCT05103202 -
Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
|
||
Completed |
NCT04423341 -
Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm
|
Phase 2/Phase 3 | |
Completed |
NCT00411255 -
Brain Stimulation to Treat Blepharospasm or Meige Syndrome
|
Phase 2 | |
Completed |
NCT00500799 -
Brain Changes in Blepharospasm
|
N/A | |
Completed |
NCT00761592 -
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
|
Phase 4 | |
Completed |
NCT00001784 -
Mexiletine for the Treatment of Focal Dystonia
|
Phase 2 | |
Recruiting |
NCT04939909 -
Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm
|
Early Phase 1 | |
Completed |
NCT03508882 -
Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm
|
Phase 4 | |
Completed |
NCT01814774 -
A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
|
N/A | |
Completed |
NCT00234507 -
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
|
Phase 2 | |
Recruiting |
NCT05618470 -
Wumeiwan Jiawei Fang Use in Patients With Blepharospasm
|
Phase 2/Phase 3 |